摘要
目的分析北京地区抗病毒药物对慢性乙肝患者治疗的现状、疗效及对预后的影响。方法采用回顾性前瞻研究的方法。结果干扰素、拉米夫定抗病毒治疗覆盖率约40%。疗程结束时HBVDNA阴转率拉米夫定组最高,但停药随访时180/220例出现反跳。干扰素组HBeAg血清转换率(22.9%)高于其他组,有统计学意义。干扰素及拉米夫定治疗者病情进展较慢且肝硬化、肝癌发生率明显低于非抗病毒组(P<0.001)。E系统转换组的并发症和死亡率明显低于非转换组(P<0.05)。结论北京地区干扰素和拉米夫定抗病毒治疗覆盖率高于其他地区,效果优于其他药物组,但总体疗效仍较低。干扰素等抗病毒治疗能减缓病情进展和减少肝硬化、肝癌的发生率。
Objective To analyze the effects of difference antiviral agents and the effects of the treatments on long-term prognosis. Methods Retrospective research method was applied. Results About 40% of the patients were treated with interferon or lamivudine. After the treatment, in lamivudine group, the negative rate of HBV DNA was the highest. In the interferon group, the sero conversion rates of HBeAg/HBeAb were 22.9% . In the antiviral treatment patients, the disease progression and the occurrence of cirrhosis and liver cancer were much lower than those of the control groups. The mortality of cirrhosis and liver cancer in the HBeAg/HBeAb sero converted group was much lower than that of the group without HBeAg/HBeAb sero eonversion groups （P 〈 0.05 ）. Conclusion The antiviral effects of interferon and lamivudine were better than those of the other drug groups. The antiviral drugs could relieve the disease progression and reduce the mortality of cirrhosis and liver cancer.
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
北大核心
2006年第3期219-222,共4页
Chinese Journal of Experimental and Clinical Virology
基金
北京市科委病毒性肝炎重大项目(H020920020690)
关键词
肝炎
乙型
慢性
抗病毒药
预后
Hepatitis B, Chronic
Antiviral agents
Prognosis
